Focus on Key Cancer Immunotherapy Patents Highlights Industry Patent Dispute
 |
| (Source: https://www.amgen.com/stories/2023/11/any-target-every-time?_gl=1*8axntp*_up*MQ..*_ga*MjQxNTA3NjExLjE3NDA4NDM3MjU.*_ga_CBMSV0J9VL*MTc0MDg0MzcyNC4xLjEuMTc0MDg0Mzc5Mi4wLjAuMA..) |
By PatenTrip
Amgen has initiated three inter partes review (IPR) petitions before the U.S. Patent Trial and Appeal Board (PTAB) against Bristol Myers Squibb as of February 28, 2025.
The petitions target patents US11,332,529 (Methods of Treating Colorectal Cancer), US10,174,113 (Treatment of PD-L1-negative Melanoma Using an Anti-PD-1 Antibody and an Anti-CTLA-4 Antibody), and US9,856,320 (Cancer Immunotherapy by Disrupting PD-1/PD-L1 Signaling).
All three patents pertain to core technologies in cancer immunotherapy that leverage immune checkpoint inhibitors. Specifically, the '529 patent describes a treatment method tailored for colorectal cancer patients; the '113 patent outlines a dual checkpoint blockade strategy designed for PD-L1-negative melanoma patients; and the '320 patent explains a broader approach to disrupting PD-1/PD-L1 signaling applicable to multiple cancer types.
Notably, Amgen has not yet been subject to a U.S. patent infringement lawsuit from Bristol Myers Squibb.
By PatenTrip
Comments
Post a Comment